Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Transl Oncol ; 22(8): 1312-1320, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31863355

RESUMO

OBJECTIVE: To analyze the relationship between therapeutic (weight-adjusted) dose of bemiparin and anti-Xa activity in patients with venous thromboembolism (VTE) and cancer in comparison with a cohort of patients with VTE without cancer, and its relationship with outcomes. MATERIALS AND METHODS: This is a prospective cohort study that comprised a cohort of patients with cancer-associated VTE and a cohort of non-cancer patients with VTE, all of them treated with bemiparin. The ethics committee approved the study and informed consent was obtained from the patients. RESULTS: One hundred patients were included (52 with cancer and 48 without cancer), with a median follow-up of 9.8 months. Mean anti-Xa activity was 0.89 (± 0.33) UI/mL in oncological patients and 0.83 (± 0.30) UI/mL in non-cancer patients (mean difference - 0.05 95% CI - 0.18; 0.06). A multiple linear regression model showed that anti-Xa peak was associated with the dose/kg independently of possible confounding variables (presence of cancer, age, sex and eGFR-estimated Glomerular Filtration Rate), in a way that for every 1 UI of dose/kg increase, the anti-Xa peak activity increased 0.006 UI/mL (95% CI 0.003; 0.009) (p < 0.001). The predictive capacity of anti-Xa peak in the oncology cohort showed an area under the ROC curve of 0.46 (95% CI 0.24-0.68), 0.70 (95% CI 0.49-0.91) and 0.74 (95% CI 0.44-0.94) for death, first bleeding and recurrence of VTE, respectively, and none was statistically significant. CONCLUSION: In patients with venous thromboembolism treated with bemiparin, anti-Xa levels were not influenced by the presence of cancer.


Assuntos
Anticoagulantes/uso terapêutico , Inibidores do Fator Xa/sangue , Heparina de Baixo Peso Molecular/uso terapêutico , Neoplasias/complicações , Tromboembolia Venosa/sangue , Idoso , Anticoagulantes/efeitos adversos , Feminino , Hemorragia/induzido quimicamente , Heparina de Baixo Peso Molecular/efeitos adversos , Humanos , Modelos Lineares , Masculino , Neoplasias/sangue , Estudos Prospectivos , Insuficiência Renal/diagnóstico , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/etiologia
3.
Med Clin (Barc) ; 114(9): 331-2, 2000 Mar 11.
Artigo em Espanhol | MEDLINE | ID: mdl-10786332

RESUMO

BACKGROUND: Wine polyphenols have antioxidant properties. Different polyphenols have various biological activities on atherogenesis and carcinogenesis. MATERIAL AND METHODS: The composition on 5 polyphenols of 16 wines of Castilla (Spain) is determined by HPLC. RESULTS: Polyphenols concentrations varied largely among the different wines. Most red wines had higher amounts of polyphenols than white wines. CONCLUSIONS: The diverse composition on polyphenols of each wine allows to suggest different biological effects.


Assuntos
Flavonoides , Fenóis/análise , Fenóis/farmacologia , Polímeros/análise , Polímeros/farmacologia , Vinho/análise , Polifenóis , Espanha
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA